High Interleukin-6 Levels Are Associated With Large-Artery Atherosclerotic Stroke.
Journal
The neurologist
ISSN: 2331-2637
Titre abrégé: Neurologist
Pays: United States
ID NLM: 9503763
Informations de publication
Date de publication:
01 Sep 2023
01 Sep 2023
Historique:
medline:
26
9
2023
pubmed:
31
1
2023
entrez:
30
1
2023
Statut:
epublish
Résumé
Interleukins (ILs) play several critical roles in modulating the occurrence and development of atherosclerosis-related diseases. We aimed to investigate the associations between ILs and the diagnosis, progress, and functional outcome in patients with large-artery atherosclerotic (LAA) stroke. Plasma levels of IL-2, IL-4, IL-6, and IL-10 were measured within 24 hours after stroke in 181 patients with first-time LAA stroke and on admission in 181 age-matched and sex-matched controls. NIHSS scores were recorded at admission and on Day 1, Day 2, Day 3, Day 4, and Day 5 after the stroke. Functional outcome was measured by the modified Rankin Scale at 3 months after stroke. Subgroup analyses were compared based on short-term progress within 5 days (ΔNIHSS ≥3) and 3-month unfavorable outcome (modified Rankin Scale >2). Logistic regression analysis adjusted for relevant confounders was performed. IL-6 levels were higher in patients with LAA stroke than in controls [AOR (95% CI), 0.701 (95% CI 0.651-0.748, P <0.001], with an area under the receiver operating characteristic curve (AUC) of 0.701. Higher IL-6 levels were associated with short-term progression [AOR (95% CI), 1.070 (1.009, 1.135), P =0.025], with an AUC value of 0.720. Higher IL-6 levels were associated with unfavorable outcomes [AOR (95% CI), 1.075 (1.002, 1.153), P =0.040], with an AUC value of 0.658. No difference in IL-2, IL-4, or IL-10 was found between the groups. Plasma levels of IL-6 are higher in patients with LAA stroke and are independently associated with short-term progression and 3-month functional outcomes after stroke.
Identifiants
pubmed: 36715665
doi: 10.1097/NRL.0000000000000483
pii: 00127893-990000000-00054
doi:
Substances chimiques
Interleukin-6
0
Interleukin-10
130068-27-8
Interleukin-2
0
Interleukin-4
207137-56-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
277-280Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;394:1145–1158.
Dhillon PS, Butt W, Podlasek A, et al. Perfusion Imaging for Endovascular Thrombectomy in Acute Ischemic Stroke Is Associated With Improved Functional Outcomes in the Early and Late Time Windows. Stroke. 2022;53:2770–2778.
Wafa HA, Wolfe CDA, Bhalla A, et al. Long-term trends in death and dependence after ischaemic strokes: A retrospective cohort study using the South London Stroke Register (SLSR). PLoS Med. 2020;17:e1003048.
Icso JD, Thompson PR. The chemical biology of NAD(+) regulation in axon degeneration. Curr Opin Chem Biol. 2022;69:102176.
Kong P, Cui ZY, Huang XF, et al. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. Signal Transduct Target Ther. 2022;7:131.
Ridker PM. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis. Circ Res. 2019;124:437–450.
Endres M, Moro MA, Nolte CH, et al. Immune pathways in etiology, acute phase, and chronic sequelae of ischemic stroke. Circ Res. 2022;130:1167–1186.
Su JH, Luo MY, Liang N, et al. Interleukin-6: A novel target for cardio-cerebrovascular diseases. Front Pharmacol. 2021;12:745061.
Boland J, Long C. Update on the Inflammatory Hypothesis of Coronary Artery Disease. Curr Cardiol Rep. 2021;23:6.
Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35–41.
Brott T, Adams HP Jr, Olinger CP, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864–870.
Jin J, Huang R, Chen Q, et al. Carotid artery perivascular adipose tissue density relates to recanalization and clinical outcome after mechanical thrombectomy. Front Aging Neurosci. 2021;13:761248.
Ridker PM, Rane M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease. Circ Res. 2021;128:1728–1746.
Eltoft A, Arntzen KA, Wilsgaard T, et al. Interleukin-6 is an independent predictor of progressive atherosclerosis in the carotid artery: The Tromso Study. Atherosclerosis. 2018;271:1–8.
Kamtchum-Tatuene J, Saba L, Heldner MR, et al. Interleukin-6 predicts carotid plaque severity, vulnerability, and progression. Circ Res. 2022;131:e22–e33.
Georgakis MK, Malik R, Gill D, et al. Interleukin-6 signaling effects on ischemic stroke and other cardiovascular outcomes: a mendelian randomization study. Circ Genom Precis Med. 2020;13:e002872.
Batra G, Ghukasyan Lakic T, Lindback J, et al. Interleukin 6 and cardiovascular outcomes in patients with chronic kidney disease and chronic coronary syndrome. JAMA cardiology. 2021;6:1440–1445.
Seners P, Turc G, Oppenheim C, et al. Incidence, causes and predictors of neurological deterioration occurring within 24 h following acute ischaemic stroke: a systematic review with pathophysiological implications. J Neurol Neurosurg Psychiatry. 2015;86:87–94.
Safouris A, Magoufis G, Tsivgoulis G. Emerging agents for the treatment and prevention of stroke: progress in clinical trials. Expert Opin Investig Drugs. 2021;30:1025–1035.
Papadopoulos A, Palaiopanos K, Bjorkbacka H, et al. Circulating interleukin-6 levels and incident ischemic stroke: a systematic review and meta-analysis of prospective studies. Neurology. 2022;98:e1002–e1012.
Sakata H, Narasimhan P, Niizuma K, et al. Interleukin 6-preconditioned neural stem cells reduce ischaemic injury in stroke mice. Brain: a journal of neurology. 2012;135(Pt 11):3298–3310.
Chen H, He Y, Chen S, et al. Therapeutic targets of oxidative/nitrosative stress and neuroinflammation in ischemic stroke: Applications for natural product efficacy with omics and systemic biology. Pharmacol Res. 2020;158:104877.
Kowalska K, Klimiec E, Weglarczyk K, et al. Reduced ex vivo release of pro-inflammatory cytokines and elevated plasma interleukin-6 are inflammatory signatures of post-stroke delirium. J Neuroinflammation. 2018;15:111.
Jiang L, Hu Y, He X, et al. Breviscapine reduces neuronal injury caused by traumatic brain injury insult: partly associated with suppression of interleukin-6 expression. Neural Regen Res. 2017;12:90–95.
Bustamante A, Sobrino T, Giralt D, et al. Prognostic value of blood interleukin-6 in the prediction of functional outcome after stroke: a systematic review and meta-analysis. J Neuroimmunol. 2014;274:215–224.
Zhang L, Xu D, Zhang T, et al. Correlation between interleukin-6, interleukin-8, and modified early warning score of patients with acute ischemic stroke and their condition and prognosis. Ann Palliat Med. 2021;10:148–155.
Li J, Lin J, Pan Y, et al. Interleukin-6 and YKL-40 predicted recurrent stroke after ischemic stroke or TIA: analysis of 6 inflammation biomarkers in a prospective cohort study. J Neuroinflammation. 2022;19:131.
Worthmann H, Tryc AB, Dirks M, et al. Lipopolysaccharide binding protein, interleukin-10, interleukin-6 and C-reactive protein blood levels in acute ischemic stroke patients with post-stroke infection. J Neuroinflammation. 2015;12:13.